Premium
Photodynamic therapy with recombinant adenovirus AdmIL‐12 enhances anti‐tumour therapy efficacy in human papillomavirus 16 (E6/E7) infected tumour model
Author(s) -
Park Eun Kyung,
Bae SuMi,
Kwak SunYoung,
Lee Sung Jong,
Kim YongWook,
Han ChanHee,
Cho HyunJung,
Kim Kyung Tae,
Kim YoungJae,
Kim HyunJung,
Ahn Woong Shick
Publication year - 2008
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1111/j.1365-2567.2007.02797.x
Subject(s) - photodynamic therapy , ctl* , cancer research , immune system , cytotoxic t cell , immunotherapy , adjuvant , cd8 , medicine , interferon gamma , in vivo , immunology , cancer , tumor necrosis factor alpha , cytokine , biology , in vitro , chemistry , biochemistry , microbiology and biotechnology , organic chemistry
Summary Immunotherapy with photodynamic therapy (PDT) offers great promise as a new alternative for cancer treatment; however, its use remains experimental. Here we investigated the utility of adenoviral delivery of interleukin‐12 (AdmIL‐12) as an adjuvant for PDT in mouse tumour challenge model. PDT was performed by irradiating Radachlorin in C57BL/6 mice transplanted with TC‐1 cells. PDT plus AdmIL‐12 treatment for tumour suppression as well as specific immune responses were evaluated with the following tests: in vitro and in vivo tumour growth inhibition, interferon‐γ (IFN‐γ) and tumour necrosis factor‐α (TNF‐α) assay, and cytotoxic T lymphocyte (CTL) assay. Direct intratumoral injection of AdmIL‐12 resulted in a significant suppression of tumour growth compared to the control group. Treatment of PDT along with AdmIL‐12 further enhanced antitumour effects significantly higher than either AdmIL‐12 or PDT alone. This combined treatment resulted in complete regression of 9‐mm sized tumour in every animal. We also evaluated immune responses induced by these treatments. Combined treatment significantly increased the production level of IFN‐γ and TNF‐α compared with that by AdmIL‐12 or PDT alone. PDT plus AdmIL‐12 enhanced antitumour immunity through increased expansion of the CTL subset mediated by CD8 + T cells. Taken together, these results indicate that the high anti‐cancer activity of PDT with AdmIL‐12 is a powerful tool against cancer therapy and is a promising subject for further investigation.